|
tbar.gif
Click
here to
submit entries
|
|
|
Amgen
Temporarily Prevails in Legal Battle with Roche
|
February
28, 2008--Amgen
won a preliminary injunction that temporarily prevents Roche from
launching its anemia drug Mircera (methoxy polyethylene glycol-epoetin beta) in
the United States. US District Court Judge William Young said he would
consider allowing Roche to launch Mircera in the US if Roche agreed to pay
Amgen a slightly higher royalty than it had initially proposed, and ensure
that it wouldn’t charge prices above those for existing anemia drugs. In
October, a jury said that Mircera infringes 11 Amgen patent claims; Roche
hasn’t brought Mircera to market in the US pending a ruling on the
injunction. CNNMoney.com
|
|
|
Genstruct: Patience, Persistence, and Payoff
By John Russell |
|
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.
Click
here
|
|
|
